Vivace Therapeutics Raises $35 Million in Series D Financing to Support Clinical Development of First-in-Class Cancer Drug Targeting the Hippo Pathway
Financing Led by RA Capital Management with Participation from Other Existing InvestorsCanaan Partners and Cenova Capital VT3989 is the Only TEAD Autopalmitoylation Inhibitor for which Compelling Clinical EfficacyData Have Been Reported, Highlights Best-in-Class Profile Funding…